These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8151800)

  • 1. Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound.
    Andries K; Rombaut B; Dewindt B; Boeyé A
    J Virol; 1994 May; 68(5):3397-400. PubMed ID: 8151800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilisation of poliovirus with pirodavir.
    Rombaut B; Andries K; Boeyé A
    Dev Biol Stand; 1996; 87():173-80. PubMed ID: 8854015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.
    Thys B; De Palma AM; Neyts J; Andries K; Vrijsen R; Rombaut B
    Antiviral Res; 2008 Jun; 78(3):278-81. PubMed ID: 18294707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat stabilized, infectious poliovirus.
    Ofori-Anyinam O; Vrijsen R; Kronenberger P; Boeyé A
    Vaccine; 1995 Aug; 13(11):983-6. PubMed ID: 8525692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a capsid-stabilizing pyridazinamine, R 78206, on the eclipse and intracellular location of poliovirus.
    Ofori-Anyinam O; Vrijsen R; Kronenberger P; Boeyé A
    J Virol; 1993 Apr; 67(4):2367-9. PubMed ID: 8383247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
    Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
    Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids.
    Rombaut B; Andries K; Boeyé A
    J Gen Virol; 1991 Sep; 72 ( Pt 9)():2153-7. PubMed ID: 1716654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity.
    Andries K; Dewindt B; Snoeks J; Willebrords R; van Eemeren K; Stokbroekx R; Janssen PA
    Antimicrob Agents Chemother; 1992 Jan; 36(1):100-7. PubMed ID: 1317142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capsid and RNA stabilisation of the oral polio vaccine.
    Verheyden B; Andries K; Rombaut B
    Vaccine; 2001 Feb; 19(15-16):1899-905. PubMed ID: 11228359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the loss of infectivity of live type 3 poliovaccine on storage.
    Pipkin PA; Minor PD
    Biologicals; 1998 Mar; 26(1):17-23. PubMed ID: 9637745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thermal inactivation of oral polio vaccine: contribution of RNA and protein inactivation.
    Rombaut B; Verheyden B; Andries K; Boeyé A
    J Virol; 1994 Oct; 68(10):6454-7. PubMed ID: 8083982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain.
    Kohara M; Abe S; Komatsu T; Tago K; Arita M; Nomoto A
    J Virol; 1988 Aug; 62(8):2828-35. PubMed ID: 2839704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.
    Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM
    Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poliovirus infection without accumulation of eclipse particles.
    Ofori-Anyinam O; Vrijsen R; Kronenberger P; Boeyé A
    Antiviral Res; 1995 Jan; 26(1):27-35. PubMed ID: 7741519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thermostabilization of live virus vaccines by heavy water (D2O).
    Wu R; Georgescu MM; Delpeyroux F; Guillot S; Balanant J; Simpson K; Crainic R
    Vaccine; 1995 Aug; 13(12):1058-63. PubMed ID: 7491812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1.
    Blomqvist S; Bruu AL; Stenvik M; Hovi T
    J Gen Virol; 2003 Mar; 84(Pt 3):573-580. PubMed ID: 12604808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brunenders: a partially attenuated historic poliovirus type I vaccine strain.
    Sanders BP; Liu Y; Brandjes A; van Hoek V; de Los Rios Oakes I; Lewis J; Wimmer E; Custers JHHV; Schuitemaker H; Cello J; Edo-Matas D
    J Gen Virol; 2015 Sep; 96(9):2614-2622. PubMed ID: 26018960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
    Kersten G; Hazendonk T; Beuvery C
    Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity.
    Barnard DL; Hubbard VD; Smee DF; Sidwell RW; Watson KG; Tucker SP; Reece PA
    Antimicrob Agents Chemother; 2004 May; 48(5):1766-72. PubMed ID: 15105133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
    Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
    Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.